US FDA puts clinical hold on Ipsen and Inspiration's hemophilia drug candidate
There was bad news for French drugmaker Ipsen (Euronext: IPN) and partner privately-held US firm Inspiration Biopharmaceuticals, as they revealed they had been notified by the US Food and Drug Administration that both clinical trials evaluating the safety and efficacy of IB1001 for hemophilia B were placed on clinical hold. This is due to the development of higher than expected rate of anti-CHO antibodies in patients treated with IB1001. The news saw Ipsen’s shares drop 11% to 17.72 euros in late afternoon trading yesterday.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze